Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cubist Appoints Reg President | Contract Pharma

What are you searching for?

Sign in
Breaking News

Cubist Appoints Reg President

Jackson to oversee all U.S. and international regulatory affairs

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Jennifer Jackson, Ph.D., has been appointed senior vice president of Regulatory Affairs at Cubist Pharmaceuticals. Dr. Jackson will oversee all regulatory affairs, providing oversight for all U.S. and international regulatory matters, including filings and interactions with regulatory authorities. Dr. Jackson will report to Steve Gilman, Ph.D., Cubist’s executive vice president of R&D and chief scientific officer.

Dr. Jackson joins the company from Biogen Idec Hemophilia, where she was vice president of Regulatory Affairs and Clinical Compliance. Prior to Biogen, Dr. Jackson was vice president of Regulatory Affairs at Vertex Pharmaceuticals and was previously director and vice president of Regulatory Affairs at Biogen Idec.

“I am delighted that Jennifer Jackson has chosen to lead Cubist’s global Regulatory Affairs team,” said Dr. Gilman. “This is a transformational year for the company, and Jennifer’s extensive international experience, collaborative nature, and focus on disciplined execution will help us as we advance our exciting pipeline in the years ahead.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics